Pioglitazone, an activator of the peroxisome proliferator-activated receptor-gamma (PPAR-γ), renowned for its insulin-sensitizing properties, has been observed to decrease the incidence of HCC in both a hospital-based case-control study and a population-based cohort study (129). The gene discussed is PPARG; the disease is hepatocellular carcinoma.